SciSparc Ltd. SPRC

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —$1.3M$2.9M$1.3M——————
SG&A —————$1.9M$2.5M$4.4M——
Operating income —-$7.3M-$6.8M-$8.3M-$5.8M-$3.3M-$4.1M-$7.2M-$5.8M-$2.0M
Net income —-$7.5M-$5.9M-$2.6M-$5.8M-$3.5M-$4.7M-$8.9M-$6.2M-$2.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets —$10.3M$11.2M$10.6M$9.9M$2.6M$1.2M$4.6M$9.6M$1.2M
Total equity —$8.9M$9.6M$6.4M$8.1M$1.4M$14.0K$77.0K$8.4M$573.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-091427.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Goodwill
  • Total assets
  • Depreciation and amortisation
Goodwill, Total assets, Depreciation and amortisation by fiscal year, in US dollars The same figures are in the table below this chart. 0 5M 10M 15M Total assets, FY2016: 1.2M Total assets, FY2017: 9.6M Total assets, FY2018: 4.6M Total assets, FY2019: 1.2M Total assets, FY2020: 2.6M Total assets, FY2021: 9.9M Total assets, FY2022: 10.6M Total assets, FY2023: 11.2M Total assets, FY2024: 10.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Goodwill — — — — — — — — — —
Total assets $1.2M $9.6M $4.6M $1.2M $2.6M $9.9M $10.6M $11.2M $10.3M —
Depreciation and amortisation — — — — — — — — — —

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
AKTX Akari Therapeutics Plc $1.79T — —
LLY ELI LILLY & Co $1.08T 50.1x 44.7%
JNJ JOHNSON & JOHNSON $663.28B 25.0x 6.0%
ONC BeOne Medicines Ltd. $529.55B 1,885.6x 40.2%
ABBV AbbVie Inc. $453.19B 108.7x 8.6%
MRK Merck & Co., Inc. $370.89B 20.6x 1.3%
ABT ABBOTT LABORATORIES $188.69B 29.1x 5.7%
PFE PFIZER INC $162.16B 20.9x -1.6%